Evidence map›Paper›PMID 40442449›Full record

ArticleJournal of thrombosis and thrombolysis2025

Enhanced recovery and abbreviated length of anticoagulation for thromboprophylaxis after primary hip arthroplasty rationale and design of the ENABLE-hip trial.

Philipp Drees, Irene Schmidtmann, Manuel Herbst, Dorothea Becker, Stefano Barco, Frederikus A Klok, Karsten Keller, Lukas Hobohm, Konstantinos C Christodoulou, Christina Abele and 19 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06611319 (ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06611319 phase3recruitingnot on this map

ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty

TypeinterventionalSponsorProf. Stavros Konstantinides, MDRan2024 to 2027Enrolled2,932ConditionsHip Arthroplasty, Total, Prevention of Venous ThromboembolismArmsPrevention of Venous Thromboembolism, Placebo Oral Tablet
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Philipp DreesCenter for Orthopedics and Trauma Surgery, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Irene SchmidtmannInstitute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Manuel HerbstInstitute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Dorothea BeckerCenter for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Stefano BarcoCenter for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Frederikus A KlokCenter for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Karsten KellerCenter for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Lukas HobohmCenter for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Konstantinos C ChristodoulouCenter for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Christina AbeleCenter for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Rupert BauersachsCardioangiologic Center Bethanien CCB, Frankfurt Am Main, Germany.
Walter AgenoDepartment of Internal Medicine, University of Padua, Padua, Italy.
Erik Lerkevang GroveDepartment of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
Henrik KehletSection for Surgical Pathophysiology, Rigshospitalet, Copenhagen, Denmark.
Friedhelm Hufen, Mainz, Germany.
Thomas KlonschinskiCenter for Orthopedics and Trauma Surgery, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Yama AfghanyarCenter for Orthopedics and Trauma Surgery, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Lukas EckhardJoint Surgery Center, Bad Kreuznach, Germany.
Nadine MartinCenter for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Susanne FischerCenter for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Stanislav GorbulevInterdisciplinary Center for Clinical Trials, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Dominik RathDepartment of Cardiology and Angiology, University Hospital Tübingen, Tübingen, Germany.
Anna C MavromanoliCenter for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Claude JabbourDepartment of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, First Department of Medicine, Medical Faculty Mannheim, University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany.
Irene LangDepartment of Internal Medicine II, Medical University of Vienna, Cardiology, Austria.
Francis CouturaudUniv_Brest, INSERM U1304-GERBI, CIC INSERM, 1412, Brest, France.
Christian HeissTrauma, Hand and Reconstructive Surgery, Justus Liebig University, Giessen, Germany.
Harald BinderInstitute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
Stavros KonstantinidesCenter for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany. stavros.konstantinides@unimedizin-mainz.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surgical total hip arthroplasty (THA) is associated with high risk of venous thromboembolism (VTE), but the appropriate duration of postoperative anticoagulation remains controversial. "Enhanced Recovery and Abbreviated Length of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty" (ENABLE-Hip) is a multicenter investigator-initiated and academically sponsored randomized double-blind active-control non-inferiority trial. Patients will be mobilized early after surgery, following a standardized enhanced recovery protocol. After an initial open-label prophylactic anticoagulation as per local standard of care until day 2 after surgery, treatment with rivaroxaban (10 mg once daily) will be started on day 3 and continued until day 10. Subsequently, patients will be switched to placebo in the experimental arm, or continue on active drug in the control arm, until a total of 35 days. The primary endpoint is acute symptomatic or fatal VTE within 3 months. A sample size of 2,932 patients will provide ≥ 80% power to reject the null hypothesis that δ ≥ 0.01 (δ = difference between the two arms in symptomatic VTE probability) at a significance level α = 0.05. An interim analysis will be performed after 3-month follow-up of the first 1,760 randomized patients at a significance level α = 0.50, leading to stop for futility if significance is not obtained, or if recalculation yields a sample size of > 3,200 patients. ENABLE-Hip will be the first major randomized trial to test an overall reduction in the duration of post-THA thromboprophylaxis and will inform future guideline recommendations concerning this continuously growing patient population.Trial registration: ClinicalTrials.gov Identifier: NCT06611319.

Indexed as

AnticoagulantsArthroplasty, Replacement, HipPostoperative ComplicationsRivaroxabanVenous ThromboembolismDouble-Blind MethodEquivalence Trials as TopicFemaleHumansMaleMulticenter Studies as TopicRandomized Controlled Trials as TopicAnticoagulantsRivaroxabanAnticoagulationRandomized controlled trialThromboprophylaxisTotal hip arthroplastyVenous thromboembolism

Identifiers

PMID40442449
PMCPMC12350570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.